Tycho Heimbach

Tycho Heimbach

Auto-generated profile, based on publicly available information

Tycho Heimbach

Pharmaceutical Sciences and Clinical Supply

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2020 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
THTycho Heimbach
Tycho Heimbach
YCYuan Chen
Yuan Chen
JCJun Chen
Jun Chen
VDVaishali Dixit
Vaishali Dixit
NPNeil Parrott
Neil Parrott
SHStephen Hall
Stephen Hall
The predictive performance of physiologically‐based pharmacokinetics (PBPK) models for pharmacokinetics (PK) in renal impairment (RI) and hepatic impairment (HI) populations was evaluated using clinical data from 29 compounds with 106 organ impairment study arms were collected from 19 member companies of the International Consortium for Innovation and Quality in Pharmaceutical Development. Fifty RI and 56 HI study arms with varying degrees of organ insufficiency along with control populations were evaluated. For RI, the area under the curve (AUC) ratios of RI to healthy control were predicted within twofold of the observed ratios for > 90% (N = 47/50 arms). For HI, > 70% (N = 43/56 arms) of the hepatically impaired to healthy control AUC ratios were predicted within twofold. Inaccuracies, typically overestimation of AUC ratios, occurred more in moderate and severe HI. PBPK predictions can help determine the need and timing of organ impairment study. It may be suitable for predicting the impact of RI on PK of drugs predominantly cleared by metabolism with varying contribution of renal clearance. PBPK modeling may be used to support mild impairment study waivers or clinical study design.


30 September 2024 in Molecular Pharmaceutics
Verified
Journal Article
Open access
THTycho Heimbach
Tycho Heimbach
FTFlora Musuamba Tshinanu
Flora Musuamba Tshinanu
KRKimberly Raines
Kimberly Raines
LBLuiza Borges
Luiza Borges
SKShinichi Kijima
Shinichi Kijima
CMClaire Mackie
Claire Mackie
The proceedings from the 30th August 2023 (Day 2) of the workshop "Physiologically Based Biopharmaceutics Models (PBBM) Best Practices for Drug Product Quality: Regulatory and Industry Perspectives" are provided herein. Day 2 covered PBBM case studies from six regulatory authorities which provided considerations for model verification, validation, and application based on the context of use (COU) of the model. PBBM case studies to define critical material attribute (CMA) specification settings, such as active pharmaceutical ingredient (API) particle size distributions (PSDs) were shared. PBBM case studies to define critical quality attributes (CQAs) such as the dissolution specification setting or to define the bioequivalence safe space were also discussed. Examples of PBBM using the credibility assessment framework, COU and model risk assessment, as well as scientific learnings from PBBM case studies are provided. Breakout session discussions highlighted current trends and barriers to application of PBBMs including: (a) PBBM credibility assessment framework and level of validation, (b) use of disposition parameters in PBBM and points to consider when iv data are not available, (c) conducting virtual bioequivalence trials and dealing with variability, (d) model acceptance criteria, and (e) application of PBBMs for establishing safe space and failure edges.

16 December 2024 in Molecular Pharmaceutics
Verified
Journal Article
Open access
CTChrister Tannergren
Christer Tannergren
SASumit Arora
Sumit Arora
ABAndrew Babiskin
Andrew Babiskin
LBLuiza Borges
Luiza Borges
PCParnali Chatterjee
Parnali Chatterjee
BRBhagwant Rege
Bhagwant Rege
This report summarizes the proceedings for Day 3 of the workshop titled "Physiologically Based Biopharmaceutics Modeling (PBBM) Best Practices for Drug Product Quality: Regulatory and Industry Perspectives". This day focused on the current and future drug product quality applications of PBBM from the innovator and generic industries as well as the regulatory agencies perspectives. The presentations, which included several case studies, covered the applications of PBBM in generic drug product development, applications of virtual bioequivalence trials to support formulation bridging and the utility of absorption modeling in clinical pharmacology assessments. In addition, recent progress in the prediction of colon absorption and in vivo performance of extended-release drug products was shared. The morning session was concluded by representatives from FDA, ANVISA, MHRA, Health Canada, EMA, and PMDA giving their perspectives on the application of PBBM in regulatory submissions. The afternoon breakout sessions focused on four parallel topics: 1) PBBM in generic drug product development; 2) virtual bioequivalence trials applications; 3) safe space and extrapolation; and 4) regional absorption and modified release PBBM applications. This allowed the participants to engage in in-depth discussions of best practices as well to identify key points of consideration to allow further progress on the applications of PBBM.

29 November 2022 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Open access
RMRandolph P. Matthews
Randolph P. Matthews
XZXiaowei Zang
Xiaowei Zang
SBStephanie E Barrett
Stephanie E Barrett
AKAthanas Koynov
Athanas Koynov
AGAdrian Goodey
Adrian Goodey
MIMarian Iwamoto
Marian Iwamoto
Background: Islatravir (MK-8591) is a deoxyadenosine analog in development for the treatment and prevention of HIV-1 infection. An islatravir-eluting implant could provide an additional option for pre-exposure prophylaxis (PrEP). Setting: Previous data support a threshold islatravir triphosphate concentration for PrEP of 0.05 pmol/106 cells in peripheral blood mononuclear cells. Prototype islatravir-eluting implants were previously studied to establish general tolerability and pharmacokinetics (PKs) of islatravir relative to the threshold level. Methods: In this randomized, double-blind, placebo-controlled, phase 1 trial, a next-generation radiopaque islatravir-eluting implant (48 mg, 52 mg, or 56 mg) or placebo implant was placed for a duration of 12 weeks in participants at low risk of HIV infection. Safety and tolerability, as well as PK for islatravir parent and islatravir triphosphate from plasma and peripheral blood mononuclear cells, were assessed throughout placement and 8 weeks after removal. Results: In total, 36 participants (8 active and 4 placebo per dose arm) were enrolled and completed this study. Implants were generally well tolerated, with no discontinuations due to an adverse event, and no clear dose-dependence in implant-related adverse events. No clinically meaningful relationships were observed for changes in laboratory values, vital signs, or electrocardiogram assessments. Mean islatravir triphosphate levels at day 85 (0.101–0.561 pmol/106 cells) were above the PK threshold for all dose levels. Conclusion: Islatravir administered using a subdermal implant has the potential to be an effective and well-tolerated method for administering PrEP to individuals at risk of acquiring HIV-1.

18 October 2020 in The AAPS Journal
Verified
Journal Article
Closed access
PDF file
MGMonika Gajewska
Monika Gajewska
LBLars Blumenstein
Lars Blumenstein
AKAlexandros Kourentas
Alexandros Kourentas
MMMartin Mueller-Zsigmondy
Martin Mueller-Zsigmondy
SLSebastien Lorenzo
Sebastien Lorenzo
THTycho Heimbach
Tycho Heimbach